Evidence map›Paper›PMID 31874858›Full record

ArticleCancer research2020

Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.

Henrik Failmezger, Sathya Muralidhar, Antonio Rullan, Carlos E de Andrea, Erik Sahai, Yinyin Yuan

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Spatially resolved C1QCCell discovery · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Henrik Failmezger *Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Sathya Muralidhar *Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Antonio RullanTumor Cell Biology Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-7365-9629
Carlos E de AndreaClinica Universidad de Navarra, Pamplona, Spain.
Erik SahaiTumor Cell Biology Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-3932-5086
Yinyin YuanCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom. yinyin.yuan@icr.ac.uk.
Institute of Cancer Research · GBClinica Universidad de Navarra · ESRoyal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GB

Funding

Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2018 to 2023
$11.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCISR01CA185138 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2014 to 2017
$2.0M
Cancer Research UK 21808Cancer Research UK C45982/A21808NCI NIH HHS R01 CA185138NCI NIH HHS U2C CA233254NCI NIH HHS U54 CA217376Wellcome Trust 105104/Z/14/ZWellcome Trust FC001144
6 · The paper itself

Abstract

Despite the advent of immunotherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome. The successful application of immunotherapy requires in-depth understanding of the biological basis and immunosuppressive mechanisms within the tumor microenvironment. In this study, we conducted spatially explicit analyses of the stromal-immune interface across 400 melanoma hematoxylin and eosin (H&E) specimens from The Cancer Genome Atlas. A computational pathology pipeline (CRImage) was used to classify cells in the H&E specimen into stromal, immune, or cancer cells. The estimated proportions of these cell types were validated by independent measures of tumor purity, pathologists' estimate of lymphocyte density, imputed immune cell subtypes, and pathway analyses. Spatial interactions between these cell types were computed using a graph-based algorithm (topological tumor graphs, TTG). This approach identified two stromal features, namely stromal clustering and stromal barrier, which represented the melanoma stromal microenvironment. Tumors with increased stromal clustering and barrier were associated with reduced intratumoral lymphocyte distribution and poor overall survival independent of existing prognostic factors. To explore the genomic basis of these TTG-derived stromal phenotypes, we used a deep learning approach integrating genomic (copy number) and transcriptomic data, thereby inferring a compressed representation of copy number-driven alterations in gene expression. This integrative analysis revealed that tumors with high stromal clustering and barrier had reduced expression of pathways involved in naïve CD4 signaling, MAPK, and PI3K signaling. Taken together, our findings support the immunosuppressive role of stromal cells and T-cell exclusion within the vicinity of melanoma cells. SIGNIFICANCE: Computational histology-based stromal phenotypes within the tumor microenvironment are significantly associated with prognosis and immune exclusion in melanoma.

Indexed as

Models, BiologicalAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalBiomarkers, TumorBiopsyCohort StudiesDeep LearningDNA Copy Number VariationsDrug Resistance, NeoplasmFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImage Interpretation, Computer-AssistedKaplan-Meier EstimateAntineoplastic Agents, ImmunologicalBiomarkers, Tumor

Identifiers

PMID31874858
PMCPMC7985597
OpenAlexW2998141119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.